Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer

Checkpoint inhibitors have demonstrated efficacy in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). However, the majority of patients do not benefit from these agents. To improve the efficacy of checkpoint inhibitors, intratumoral (i.t.) injection with innate imm...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:JCI Insight
Autores principales: Sato-Kaneko, Fumi, Yao, Shiyin, Ahmadi, Alast, Zhang, Shannon S., Hosoya, Tadashi, Kaneda, Megan M., Varner, Judith A., Pu, Minya, Messer, Karen S., Guiducci, Cristiana, Coffman, Robert L., Kitaura, Kazutaka, Matsutani, Takaji, Suzuki, Ryuji, Carson, Dennis A., Hayashi, Tomoko, Cohen, Ezra E.W.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Clinical Investigation 2017
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5621908/
https://ncbi.nlm.nih.gov/pubmed/28931759
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.93397
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares